ENTA News and Press, Enanta Pharmaceuticals Inc. From 11/20/23

2023-11-20 16:02:57 ET More on Enanta Pharma Enanta Pharma Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Enanta Pharma Historical earnings data for Enanta Pharma Financial information for Enanta Pharma For further details see: En...

Initiated a Phase 2a Challenge Study of EDP-323, an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Report Data in Q3 2024 Streamlined Business and Significantly Lowered 2024 R&D and G&A Spending Guidance to...

AERWINS Technologies Inc. (AWIN) is expected to report for Q1 2024 Minera IRL Ltd ADR (MRLLY) is expected to report for quarter end 2023-09-30 SmileDirectClub, Inc. - Ordinary Shares - Class A (SDCCQ) is expected to report $-0.1 for Q3 2023 NextPlay Technologies Inc. (NXTP) is expecte...

Enanta Pharmaceuticals Inc. (ENTA) is expected to report $-2.11 for Q4 2023

2023-11-19 08:00:00 ET Even with the holiday-shortened Thanksgiving week, several prominent companies are set to unveil their quarterly results next week. The docket includes tech giant Nvidia ( NASDAQ: NVDA ), as well as Zoom Video ( NASDAQ: ZM ), HP Inc. ( NYSE: HPQ ...

Enanta Pharmaceuticals, Inc . (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2023 after the U.S....

Webcast to be Held on Friday, October 20, 2023 at 8:00 a.m. ET Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced it will host a virtual key opinion leader event ...

2023-10-10 15:58:09 ET More on Akero Akero Therapeutics: Contrarian Buy Opportunity As Stock Tanks On 'NASH Dash' Data Akero Therapeutics: An Assessment Biggest stock movers today: Coherent, Truist Financial, Akero Therapeutics and more Akero plummets after m...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial v...

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial v...